✦ LIBER ✦

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)

✍ Scribed by Martine Van Glabbeke; Jaap Verweij; Paolo G. Casali; John Simes; Axel Le Cesne; Peter Reichardt; Rolf Issels; Ian R. Judson; Allan T. van Oosterom; Jean-Yves Blay

Book ID: 116428999
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 187 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2006.03.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fotemustine in patients with advanced ga

Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer cooperative group)

✍ Ph. Rougier; C. Van Pottelsberghe; T. Kok; B. Paillot; T. Wagener; J. De Greve; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Performance status is the most powerful

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study

✍ Penel, N; Glabbeke, M V; Mathoulin-Pelissier, S; Judson, I; Sleijfer, S; Bui, B; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

Phase I trial of r viscumin (INN: aviscu

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)

✍ Lothar Bergmann; Steiner Aamdal; Sandrine Marreaud; Denis Lacombe; Manfred Herol 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Prognostic and predictive factors for ou

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

✍ Stefan Sleijfer; Monia Ouali; Martine van Glabbeke; Anders Krarup-Hansen; Sjoerd 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 361 KB

DNA-methylation of the homeodomain trans

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group

✍ Sabine Maier; Inko Nimmrich; Thomas Koenig; Serenella Eppenberger-Castori; Inga 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Randomized phase II/III trial of interfe

Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951): Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ, Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

✍ Robert Flanigan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB